Decitabine and its role in the treatment of hematopoietic malignancies

Elizabeth R. Plimack, Hagop M. Kantarjian, Jean Pierre Issa

Research output: Contribution to journalReview articlepeer-review

100 Scopus citations

Abstract

DNA methylation is responsible for abnormal silencing of many genes, including tumor suppressor genes, in cancer. Decitabine, an S-phase specific inhibitor of DNA methyltransferase, has been shown to decrease levels of abnormal methylation in neoplasia. Though initially investigated at high doses as a cytotoxic agent, recent studies show that when administered at low doses, the hypomethylating activity of decitabine is increased with a demonstrated increase in activity in hematopoietic malignancies. Multiple clinical trials, both in the United States and in Europe, have demonstrated the efficacy of decitabine in acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndrome (MDS). Recently approved by the United States Food and Drug Administration for the treatment of (MDS), decitabine represents an effective and well-tolerated therapeutic option in this disease, for which treatment options were previously scarce. While the activity in MDS is promising, primary and secondary resistance remain a problem. Investigations of combinations of decitabine with other agents, including histone deacetylase inhibitors, are currently ongoing in the hope of substantially prolonging survival in patients with hematologic malignancies.

Original languageEnglish
Pages (from-to)1472-1481
Number of pages10
JournalLeukemia and Lymphoma
Volume48
Issue number8
DOIs
StatePublished - Aug 2007

Keywords

  • AML
  • Decitabine
  • Epigenetics
  • MDS
  • Methylation

Fingerprint

Dive into the research topics of 'Decitabine and its role in the treatment of hematopoietic malignancies'. Together they form a unique fingerprint.

Cite this